You have been successfully logged out.
Innovative antiviral therapies have significantly improved the cure rates for HCV, transforming it from a chronic, life-threatening condition into a curable disease for many patients.1
Find out more about hepatitis C and ongoing efforts to achieve elimination in the UK.
Chronic HDV causes the most severe form of viral hepatitis and is often underdiagnosed. It can have mortality rates as high as 50% within five years for people with cirrhosis.2
Find out more about hepatitis D and the potential impact it may have on your patients.
PBC is a chronic autoimmune liver disease that slowly damages the bile ducts, potentially leading to liver failure if untreated.3
Find out more about approaches and perspectives to PBC diagnosis, management and treatment.
Sofosbuvir/Velpatasvir Gilead is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older.4
Ledipasvir/Sofosbuvir Gilead is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above.5
Please see the SmPC for hepatitis C virus (HCV) genotype-specific activity.
Sofosbuvir/Velpatasvir/Voxilaprevir Gilead is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg.6
Hepcludex® is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult and paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease.7
LIVDELZI® has received conditional marketing authorisation for the treatment of primary biliary cholangitis, including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.8
UKI-UNB-1431 | January 2026